Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -0.09%-50.63M | 31.21%-8.54M | -239.80%-15.43M | 25.20%-13.52M | 15.49%-13.14M | 19.32%-50.58M | 12.57%-12.42M | 66.11%-4.54M | 6.68%-18.07M | 1.10%-15.55M |
Net income from continuing operations | -167.60%-200.99M | -1,116.68%-152.96M | 33.23%-14.83M | 26.79%-12.42M | 11.05%-20.77M | -5.01%-75.11M | 45.03%-12.57M | -18.45%-22.22M | -38.48%-16.97M | -32.38%-23.35M |
Operating gains losses | 2,573.18%90.59M | 2,989.59%91.31M | -126.51%-1.2M | -4,385.71%-2.1M | 30.92%2.58M | 112.15%3.39M | -22.58%-3.16M | 153.32%4.53M | 100.49%49K | 129.27%1.97M |
Depreciation and amortization | -7.00%6.91M | 67.56%1.75M | -14.59%1.82M | -28.38%1.55M | -14.46%1.79M | 5.83%7.43M | -52.84%1.05M | 16.95%2.13M | 36.02%2.16M | 50.29%2.09M |
Other non cash items | 1,038.47%46.5M | 6,816.97%44.74M | -95.40%123K | -165.59%-673K | 119.79%2.31M | 123.74%4.08M | 22.20%-666K | 159.99%2.67M | 116.47%1.03M | 118.56%1.05M |
Change In working capital | -522.42%-3.08M | 6,663.93%4.13M | -170.00%-3.79M | 66.74%-2.24M | -256.76%-1.18M | 78.73%-495K | 102.95%61K | 215.26%5.41M | -96.18%-6.72M | -48.11%754K |
-Change in receivables | -25.46%1.57M | 502.70%3.73M | -115.30%-875K | 37.72%-1.95M | 52.44%657K | 138.91%2.1M | 76.57%-926K | 1,129.89%5.72M | 15.04%-3.12M | -75.57%431K |
-Change in prepaid assets | -839.77%-2.43M | -162.37%-479K | -576.81%-934K | 7.96%-1.46M | -37.23%435K | 75.68%-259K | -35.03%768K | -121.20%-138K | -1,114.10%-1.58M | 122.69%693K |
-Change in payables and accrued expense | -55.96%-2.68M | 173.28%951K | -1,151.81%-2.03M | 119.98%458K | -6,537.50%-2.06M | -138.58%-1.72M | -64.74%348K | -78.84%193K | -50.10%-2.29M | -99.22%32K |
-Change in other working capital | 175.73%468K | 41.86%-75K | 113.85%50K | 158.03%707K | 46.77%-214K | -2,475.00%-618K | -186.00%-129K | -21.55%-361K | -53.48%274K | 13.73%-402K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -0.09%-50.63M | 31.21%-8.54M | -239.80%-15.43M | 25.20%-13.52M | 15.49%-13.14M | 19.32%-50.58M | 12.57%-12.42M | 66.11%-4.54M | 6.68%-18.07M | 1.10%-15.55M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -10,237.39%-78.36M | -621.74%-77.59M | -56.16%6.27M | -208.44%-13.25M | 141.51%6.22M | 100.72%773K | -1,876.29%-10.75M | 114.91%14.29M | 256.68%12.22M | -428.42%-14.99M |
Net PPE purchase and sale | -22.51%-11.1M | 17.18%-1.28M | -28.27%-2.28M | -119.66%-2.05M | -14.34%-5.49M | 60.16%-9.06M | 55.04%-1.55M | 79.49%-1.78M | 88.06%-931K | -69.39%-4.8M |
Net investment purchase and sale | -784.13%-67.26M | -729.21%-76.31M | -46.82%8.54M | -185.22%-11.21M | 215.04%11.71M | 111.66%9.83M | -417.45%-9.2M | 118.43%16.07M | --13.15M | ---10.18M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -10,237.39%-78.36M | -621.74%-77.59M | -56.16%6.27M | -208.44%-13.25M | 141.51%6.22M | 100.72%773K | -1,876.29%-10.75M | 114.91%14.29M | 256.68%12.22M | -428.42%-14.99M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 1,226.22%175.46M | 4,871.14%133.67M | -15.24%8.69M | 759.93%12.38M | 1,894.63%20.71M | -93.86%13.23M | 264.46%2.69M | 1,614.77%10.26M | -66.67%1.44M | -100.54%-1.15M |
Net issuance payments of debt | -179.95%-23.33M | -372.58%-13.84M | -29.25%-3.29M | -197.55%-3.15M | -69.35%-3.05M | -324.67%-8.33M | -126.80%-2.93M | ---2.55M | ---1.06M | -135.96%-1.8M |
Net common stock issuance | 904.37%206.34M | 2,715.75%154.67M | -5.55%12M | 573.00%15.8M | --23.87M | --20.54M | --5.49M | --12.7M | --2.35M | --0 |
Proceeds from stock option exercised by employees | -50.80%554K | 279.84%471K | -84.85%15K | -94.74%8K | -92.01%60K | -81.44%1.13M | 58.97%124K | -68.57%99K | -97.00%152K | 24.75%751K |
Net other financing activities | -7,474.77%-8.11M | ---7.63M | ---29K | ---273K | -62.62%-174K | -100.05%-107K | --0 | --0 | --0 | -100.05%-107K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 1,226.22%175.46M | 4,871.14%133.67M | -15.24%8.69M | 759.93%12.38M | 1,894.63%20.71M | -93.86%13.23M | 264.46%2.69M | 1,614.77%10.26M | -66.67%1.44M | -100.54%-1.15M |
Net cash flow | ||||||||||
Beginning cash position | -63.05%21.39M | -51.42%20.29M | -4.73%20.68M | 34.39%35.1M | -63.05%21.39M | 380.56%57.89M | -43.54%41.76M | -88.21%21.71M | -87.38%26.12M | 380.56%57.89M |
Current changes in cash | 227.05%46.47M | 332.08%47.54M | -102.35%-470K | -226.31%-14.39M | 143.52%13.79M | -179.96%-36.58M | -25.00%-20.48M | 118.20%20M | 80.70%-4.41M | -116.26%-31.69M |
Effect of exchange rate changes | -335.00%-188K | -225.42%-148K | 75.61%72K | -775.00%-27K | -2.41%-85K | -20.79%80K | -63.13%118K | 115.47%41K | -89.19%4K | -1,022.22%-83K |
End cash Position | 216.35%67.67M | 216.35%67.67M | -51.42%20.29M | -4.73%20.68M | 34.39%35.1M | -63.05%21.39M | -63.05%21.39M | -43.54%41.76M | -88.21%21.71M | -87.38%26.12M |
Free cash flow | -3.50%-61.73M | 29.66%-9.83M | -180.32%-17.71M | 18.10%-15.56M | 8.45%-18.63M | 30.19%-59.64M | 20.86%-13.97M | 71.36%-6.32M | 30.05%-19M | -9.67%-20.35M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |